Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: The complex high-risk indicated percutaneous coronary intervention (CHIP) score is a tool developed using the British Cardiovascular Intervention Society (BCIS) database to define CHIP cases and predict in-hospital major adverse cardiac or cerebrovascular events (MACCE).
Aim: To assess the validity of the CHIP score in chronic total occlusion (CTO) percutaneous coronary intervention (PCI).
Methods: We evaluated the performance of the CHIP score on 8341 CTO PCIs from the Prospective Global Registry for the Study of Chronic Total Occlusion Intervention (PROGRESS-CTO) performed at 44 centers between 2012 and 2023.
Results: In our cohort, 7.8% (n = 647) of patients had a CHIP score of 0, 50.2% (n = 4192) had a CHIP score of 1-2, 26.2% (n = 2187) had a CHIP score of 3-4, 11.7% (n = 972) had a CHIP score of 5-6, 3.3% (n = 276) had a CHIP score of 7-8, and 0.8% (n = 67) had a CHIP score of 9+. The incidence of MACCE for a CHIP score of 0 was 0.6%, reaching as high as 8.7% for a CHIP score of 9+, confirming that a higher CHIP score is associated with a higher risk of MACCE. The estimated increase in the risk of MACCE per one score unit increase was 100% (95% confidence interval [CI]: 65%-141%). The AUC of the CHIP score model for predicting MACCE in our cohort was 0.63 (95% CI: 0.58-0.67). There was a positive correlation between the CHIP score and the PROGRESS-CTO MACE score (Spearman's correlation: 0.37; 95% CI: 0.35-0.39; p < 0.001).
Conclusions: The CHIP score has modest predictive capacity for MACCE in CTO PCI.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/ccd.31045 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
We envision the Full-Body AI Agent as a comprehensive AI system designed to simulate, analyze, and optimize the dynamic processes of the human body across multiple biological levels. By integrating computational models, machine learning tools, and experimental platforms, this system aims to replicate and predict both physiological and pathological processes, ranging from molecules and cells to tissues, organs, and entire body systems. Central to the Full-Body AI Agent is its emphasis on integration and coordination across these biological levels, enabling analysis of how molecular changes influence cellular behaviors, tissue responses, organ function, and systemic outcomes.
View Article and Find Full Text PDFTiming of first pembrolizumab infusion and long-term outcomes in non-small cell lung cancer: A retrospective multicenter study.
Eur J Cancer
August 2025
Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, The University of Osaka, Japan; Department of Immunopathology, Immunology Frontier Research Center, The University of Osaka, Japan; Centerfor Advanced Modalities and DDS, The University of Osaka, Japan; Center
Background: Circadian rhythms modulate immunity, and a preclinical study suggests that the timing of the first immune checkpoint inhibitor dose affects antitumor efficacy. However, clinical confirmation is scarce. We aimed to evaluate whether the timing of the first pembrolizumab infusion affects outcomes in unresectable non-small cell lung cancer (NSCLC).
View Article and Find Full Text PDFClonal haematopoiesis of indeterminate potential and mortality in coronary artery disease.
Eur Heart J
September 2025
Department of Cardiology, TUM Klinikum Deutsches Herzzentrum, Technical University Munich, Lazarettstr. 36, Munich D-80636, Germany.
Background And Aims: Clonal haematopoiesis of indeterminate potential (CHIP) has been associated with cardiovascular risk, but its prognostic relevance and mechanistic role in coronary artery disease (CAD) remains incompletely understood. This study investigated the association between CHIP and all-cause mortality in CAD and explored the cellular and molecular mechanisms, focusing on TET2 mutations.
Methods: Targeted deep sequencing of 13 CHIP driver genes in 8612 patients with angiographically confirmed CAD was performed.
A pilot transcriptomic study of a novel multitargeted BRT regimen for anti-MDA5 antibody-positive dermatomyositis: improving survival over conventional therapy.
Front Immunol
August 2025
Division of Rheumatology, Center for Autoimmune Diseases, Japanese Red Cross Okayama Hospital, Okayama, Japan.
Background: Anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis (MDA5-DM) is associated with severe outcomes, primarily due to rapidly progressive interstitial lung disease (RP-ILD), which is often refractory to standard therapies such as calcineurin inhibitors (e.g., tacrolimus) combined with cyclophosphamide (TC-Tx).
View Article and Find Full Text PDFCan LLMs effectively assist medical coding? Evaluating GPT performance on DRG and targeted clinical tasks.
BMC Med Inform Decis Mak
August 2025
Amplify Health Asia, 21 Collyer Quay, Singapore, 049320, Singapore.
Background: Large language Models (LLM) have demonstrated near human-level performance in medical domain, from summarizing clinical notes and passing medical licensing examinations, to predictive tasks such as disease diagnoses and treatment recommendations. However, currently there is little research on their efficacy for medical coding, a pivotal component in health informatics, clinical trials, and reimbursement management. This study proposes a prompt framework and investigates its effectiveness for medical coding.
View Article and Find Full Text PDF